Suzhou Sciscape Biomedicine Science & Technology Co. Ltd.;Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China
Disclosed in the present invention is the use of a salmonella flagellin derivative CZLC331 protein in the development of a drug for the prevention and treatment of inflammatory bowel diseases. The invention demonstrates that salmonella flagellin derivative CZLC331 protein has a good prevention and treatment effect against inflammatory bowel disease, such as ulcerative colitis and Crohn's disease and so on, so the protein can be used as the active ingredient in the preparation of a drug for the prevention and treatment of inflammatory bowel diseases. The present invention can solve the problems of current drugs for treating inflammatory bowel diseases, such as poor drug treatment effects, taking a long time to take effect, a long course of treatment and severe side effects, therefore significantly relieving the pain of patients during the treatment process, hastening the recovery of patients and improving their quality of life. The invention will play an important role in the prevention and treatment of inflammatory bowel diseases and inflammation at other sites, and it has a wide area of application.
